The ALL therapeutic landscape has changed dramatically with the incorporation of novel immunotherapies, such as the bispecific T-cell engager (BiTE) that links CD19+ B-cells with CD3+ T cells, the calicheamicin-conjugated anti-CD22 monoclonal antibody, and multiple CD19-targeted chimeric antigen receptor (CAR) T cells [4,5,6,7]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.